However, antidiabetic agents, including pioglitazone [9,10] and glucagon-like peptide-1 (GLP-1) agonists [11], are expected to reduce hepatic fat content or hepatic inflammation in NAFLD. This evidence concerns the gene GCG and metabolic dysfunction-associated steatotic liver disease.